Acquired DNA mutations in adults with myeloproliferative disorders receiving hydroxyurea therapy.

被引：0
|
作者：
Hanft, VN
Fruchtman, S
Heumayer, S
Weinberg, JB
Howard, TA
Ware, RE
机构：
[1] DUKE UNIV,MED CTR,DURHAM,NC
[2] DURHAM VA HOSP,DURHAM,NC
[3] MT SINAI HOSP,NEW YORK,NY 10029
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1542 / 1542
页数：1
相关论文
共 41 条
  • [41] Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
    Yacoub, Abdulraheem
    Mascarenhas, John
    Kosiorek, Heidi Elizabeth
    Prchal, Josef T.
    Berenzon, Dmitriy
    Baer, Maria R.
    Ritchie, Ellen K.
    Silver, Richard T.
    Kessler, Craig M.
    Winton, Elliott F.
    Finazzi, Maria Chiara
    Rambaldi, Alessandro
    Vannucchi, Alessandro M.
    Leibowitz, David S.
    Rondelli, Damiano
    Arcasoy, Murat O.
    Catchatourian, Rosalind
    Vadakara, Joseph
    Rosti, Vittorio
    Hexner, Elizabeth
    Kremyanskaya, Marina
    Orellana, Alicia
    Sandy, Lonette
    Tripodi, Joseph
    Najfeld, Vesna
    Salama, Mohamed E.
    Weinberg, Rona Singer
    Rampal, Raajit K.
    Mesa, Ruben A.
    Goldberg, Judith D.
    Dueck, Amylou C.
    Hoffman, Ronald
    BLOOD, 2017, 130
12345